Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr 17;29(4):2835-2847.
doi: 10.3390/curroncol29040231.

New Targeted Therapies and Combinations of Treatments for Cervical, Endometrial, and Ovarian Cancers: A Year in Review

Adelina Silvana Gheorghe  1 , Elena Adriana Dumitrescu  1 , Isabela Anda Komporaly  1 , Raluca Ioana Mihăilă  1 , Cristian Virgil Lungulescu  2 , Dana Lucia Stănculeanu  1
Affiliations
Review

New Targeted Therapies and Combinations of Treatments for Cervical, Endometrial, and Ovarian Cancers: A Year in Review

Adelina Silvana Gheorghe et al. Curr Oncol. .

Abstract

This review of the meaningful data from 2021 on cervical, endometrial, and ovarian cancers aims to provide an update of the most clinically relevant studies presented at important oncologic congresses during the year (the American Society of Clinical Oncology (ASCO) Annual Meeting, the European Society for Medical Oncology (ESMO) Congress and the Society of Gynecologic Oncology (SGO) Annual Meeting). Despite the underlying existence of the COVID-19 pandemic, the last year has been notable in terms of research, with significant and promising advances in gynecological malignancies. Several major studies reporting the effects of innovative therapies for patients with cervical, endometrial, and ovarian cancers might change the medical practice in the future.

Keywords: 2021 update; cervical cancer; endometrial cancer; immunotherapy; novel targeted therapies; ovarian cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. World Health Organization . WHO Guideline for Screening and Treatment of Cervical Pre-Cancer Lesions for Cervical Cancer Prevention. World Health Organization; Geneva, Switzerland: 2021. Licence: CC BY-NC-SA 3.0 IGO. - PubMed
    1. DeGroff A., Miller J., Sharma K., Sun J., Helsel W., Kammerer W., Rockwell T., Sheu A., Melillo S., Uhd J., et al. COVID-19 impact on screening test volume through the National Breast and Cervical Cancer early detection program, January–June 2020, in the United States. Prev. Med. 2021;151:106559. doi: 10.1016/j.ypmed.2021.106559. - DOI - PMC - PubMed
    1. Bowden S.J., Bodinier B., Kalliala I., Bowden S.J., Bodinier B., Kalliala I., Zuber V., Vuckovic D., Doulgeraki T., Whitaker M.D., et al. Genetic variation in cervical preinvasive and invasive disease: A genome-wide association study. Lancet Oncol. 2021;22:548–557. doi: 10.1016/S1470-2045(21)00028-0. - DOI - PMC - PubMed
    1. Ramirez P.T., Frumovitz M., Pareja R., Lopez A., Vieira M., Ribeiro R., Buda A., Yan X., Shuzhong Y., Chetty N., et al. Minimally invasive versus abdominal radical hysterectomy for cervical cancer. N. Engl. J. Med. 2018;379:1895–1904. doi: 10.1056/NEJMoa1806395. - DOI - PubMed